AlphaYou
Overview
Smart money at a glance
Filings to Oct 5, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: net buying of $1K to $15K in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- +$1K to +$15K netNet buying
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 5- Open
- $165.13
- 52-wk high
- $183.90
- High
- $167.18
- 52-wk low
- $138.32
- Low
- $163.85
- Prev close
- $163.69
- Mkt cap
- $5.31B
- P/E
- 32.8x
- Volume
- 197.3K
- Fwd P/E
- 29.3x
- Beta
- 0.81
- Div yield
- 0.59%
- P/S
- 4.9x
- P/B
- 4.1x
- Profit margin
- +15.1%
- Op margin
- +20.8%
- ROE
- +12.8%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about BCPC filings
Are insiders buying or selling Balchem Corporation (BCPC) stock?
Neither. Balchem Corporation (BCPC) insiders filed no open-market purchases or sales in the 90 days to Oct 5, 2026, according to SEC Form 4 filings.
Which members of Congress have traded BCPC recently?
Rep. Gilbert Cisneros (D) bought $1K to $15K on Jul 10, 2026, disclosed 56 days later. In total, 1 member disclosed 1 BCPC trade with trade dates in the last 180 days, filed a median 56 days after trading.
How current is this BCPC smart-money data?
This summary uses filings available on Oct 5, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (2)
- MI
Millennium
$11.3M
added
- TS
Two Sigma
$41.8M
added
What Congress is doing
Buys (1)
How top traders are positioned
No tracked top-trader positions in BCPC right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 6.4% above what analysts expected.
Last report
Jul 31, 2026
Period ending
Jun 30, 2026
Earnings per share
$1.40 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 31, 2026 | $1.49 / $1.40Alpha Vantage | +6.43% beat | Unavailable | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $1.33 / $1.33Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 20, 2026 | $1.31 / $1.18Alpha Vantage | +11.02% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 21, 2025 | $1.35 / $1.31Alpha Vantage | +3.05% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $1.27 / $1.25Alpha Vantage | +1.60% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 24, 2025 | $1.22 / $1.22Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 21, 2025 | $1.13 / $1.10Alpha Vantage | +2.26% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 25, 2024 | $1.13 / $1.12Alpha Vantage | +0.89% in line | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Oct 20, 2026, in 15 days
Estimates as of Oct 3, 2026
EPS expected
$1.51 to $1.56
Revenue expected
3 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $255.5M | $267.6M | $263.6M | $270.7M |
| Cost of what it sold | $162.4M | $172.1M | $169.7M | $169.6M |
| Gross profit | $93.1M | $95.5M | $93.9M | $101.1M |
| What it spent | ||||
| Research and development | $4.7M | $9.3M | $5.1M | $5.9M |
| Sales and admin | $18.1M | $33.1M | $1.1M | $18.5M |
| Other operating costs | $18.9M | -$1.6M | $27.6M | $21.1M |
| Total operating expenses | $41.7M | $40.9M | $33.8M | $45.5M |
| What was left | ||||
| Operating profit | $51.4M | $54.6M | $60.1M | $55.6M |
| Interest on debt | $2.8M | $2.4M | $2.2M | $3.1M |
| Profit before tax | $49.0M | $52.0M | $50.0M | $52.5M |
| Tax | $10.7M | $11.8M | $10.8M | $12.2M |
| Net profit | $38.3M | $40.3M | $39.2M | $40.3M |
| EBITDA | $63.2M | $76.8M | $63.4M | $67.2M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
15 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Balchem Corp Revenue Breakdown – HAN:BL9B
NeutralSep 29Net income before discontinued operations of Balchem Corp – HAN:BL9B
NeutralSep 29Most of the shares held directly by Balchem's (BCPC) R&D chief are restricted and vest over time.
NeutralSep 24Balchem Corporation (BCPC) Stock forecasts
BullishSep 24Balchem (BCPC) Stock Could Be 25% Undervalued On Cash Flow
BullishSep 24